Investigational Drug Shows Promise for Advanced Ovarian Cancer

A Phase I clinical trial presented at the AACR Annual Meeting 2026 revealed that the investigational antibody-drug conjugate QLS5132 demonstrated clinical benefit in patients with advanced platinum-resistant ovarian cancer. The drug, which targets the CLDN6 protein, led to objective responses and disease control in individuals whose cancer had progressed on prior treatments. These findings suggest a potential new therapeutic option for this challenging form of cancer.